Alumis, Inc.
Biotechnology
Alumis is a clinical-stage biopharmaceutical company focused on developing oral precision therapies to transform the lives of patients with immune-mediated diseases. Its approach involves leveraging a precision analytics platform and deep expertise in precision medicine drug discovery, development, and immunology.
Founded: 2021
Martin Babler President, Chief Executive Officer, and Chairman |
Mark Bradley Chief Development Officer |
Jörn Drappa, MD, Ph.D. Chief Medical Officer |
David Goldstein Chief Scientific Officer |
Roy Hardiman Chief Business and Legal Officer |
John Schroer Chief Financial Officer |